NUTH, The Netherlands and SAN DIEGO, Aug. 07, 2017 -- Fortimedix Surgical today announced the official U.S. launch of its product line extension with symphonX™ Instruments short. The new product line offers shorter instruments that broaden surgical applicability of the symphonX™ Surgical Platform, further increasing the ease of use for surgeons during specific surgical procedures.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ba3500cd-9477-42ff-a33c-8292466f85b3
symphonX™ is the world’s lowest profile single-port surgery solution for use in minimally invasive abdominal laparoscopic surgery. The symphonX™ Instruments portfolio includes various products for grasping, mobilizing, dissecting, retracting, cutting, cauterizing, ligating, and suction/irrigation of tissues and vessels. With this line extension, these different types of instruments are available in a short version. Choosing the appropriate symphonX™ Instruments for a specific surgical procedure, patient anatomy and/or operative site is at the physician’s discretion.
“This product line extension was developed in response to surgeon feedback,” said David Castiglioni, Vice President Sales of Fortimedix Surgical. “We have used these shorter instruments during cholecystectomy, inguinal hernia repair and several gynecologic procedures including tubal sterilization and ovarian cyst treatment with positive results, confirming the versatility of the platform across surgical specialties. The launch of symphonX™ Instruments short signifies a substantial milestone as we continue to execute on our strategy to establish broad based market adoption of symphonX™ and elevate the standard of care in laparoscopy.”
For additional information or product specifications on symphonX™ Instruments short visit www.fortimedixsurgical.com.
About symphonX™
symphonX™ is the world’s first single-port surgery solution compatible with a standard 15mm laparoscopic trocar. Emulating conventional, multi-port laparoscopy makes symphonX™ easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach. symphonX™ is poised to deliver on the promise of single-port surgery, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis, elevating the standard of care in laparoscopy.
About Fortimedix Surgical
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a U.S. subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for almost two decades. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.
For more information, please visit www.fortimedixsurgical.com
Forward-Looking Statements
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.
For media inquiries, please contact: Fortimedix Surgical B.V., Monique Biermans, [email protected], +31 (0)6 24 676 376 Digital press release available at: www.fortimedixsurgical.com/news-events Lazar Partners, Chantal Beaudry, [email protected], or Amy Feldman, [email protected], +1 (212) 867-1762


Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
Bill Ackman Eyes New Fund to Bet Against Market Complacency
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 



